Xu C, Zhao H, Chen H, Yao Q. CXCR4 in breast cancer: oncogenic role and therapeutic targeting. Drug Des
Devel Ther. 2015;9:4953-4964.
Lee B, Sharron M, Montaner LJ, et al. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets,
dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci U S A.
1999;96(9):5215-5220.
Loetscher M, Geiser T, O'Reilly T, et al. Cloning of a human seven-transmembrane domain receptor, LESTR,
that is highly expressed in leukocytes. J Biol Chem. 1994;269):232-237.
Helbig G, Christopherson KW II, Bhat-Nakshatri P, et al. NF-kappaB promotes breast cancer cell migration and
metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem.
2003;278(24):21631-21638.
Cheng M, Qin G. Progenitor cell mobilization and recruitment: SDF-1, CXCR4, α 4-integrin, and c-kit. Prog
Mol Biol Transl Sci. 2012;111:243-264.
Oberlin E, Amara A, Bachelerie F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents
infection by T-cell-line-adapted HIV-1. Nature. 1996,382(6594):833-835.
Sun X, Cheng G, Hao M, et al. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer
Metastasis Rev. 2010;29(4):709-722.
Sehgal A, Keener C, Boynton AL, et al. CXCR-4, a chemokine receptor, is overexpressed in and required for
proliferation of glioblastoma tumor cells. J Surg Oncol. 1998;69(2):99-104.
Chen Y, Stamatoyannopoulos G, Song C-Z. Down-regulation of CXCR4 by inducible small interfering RNA inhibits
breast cancer cell invasion in vitro. Cancer Res. 2003;63(16):4801-4804.
Righi E, Kashiwagi S, Yuan J, et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong
survival in an immunocompetent mouse model of ovarian cancer. Cancer Res. 2011;71(16):5522-5534.
Kuhne MR, Mulvey T, Belanger B, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces
apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res.
2013;19(2):357-366.